Johnson & Johnson (JNJ) Cash from Operations Growth (3y) (2012 - 2026)
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Cash from Ops. Growth (3y) (Qtr) |
| 1 |
Novartis Ag |
107,124,802.25 Bn |
107,124,802.25 Bn |
- |
- |
| 2 |
Eli Lilly |
969.00 Bn |
963.72 Bn |
16.22 Bn |
45.52% |
| 3 |
Johnson & Johnson |
539.46 Bn |
517.41 Bn |
15.96 Bn |
-8.27% |
| 4 |
AbbVie |
376.92 Bn |
367.57 Bn |
10.78 Bn |
-2.98% |
| 5 |
Merck |
285.00 Bn |
279.35 Bn |
12.09 Bn |
43.03% |
| 6 |
Amgen |
177.58 Bn |
165.55 Bn |
5.87 Bn |
27.18% |
| 7 |
Gilead Sciences |
163.22 Bn |
155.50 Bn |
5.52 Bn |
13.41% |
| 8 |
Pfizer |
145.86 Bn |
133.09 Bn |
-1.21 Bn |
29.22% |
| 9 |
Bristol Myers Squibb |
111.90 Bn |
101.44 Bn |
8.07 Bn |
-28.10% |
| 10 |
Gsk |
88.34 Bn |
83.66 Bn |
- |
- |
| Date | Value |
|---|
| Mar 29, 2026 |
-8.27% |
| Dec 28, 2025 |
27.63% |
| Mar 30, 2025 |
1.61% |
| Sep 29, 2024 |
-1.21% |
| Jun 30, 2024 |
1.96% |
| Mar 31, 2024 |
-3.54% |
| Dec 31, 2023 |
-1.96% |
| Oct 1, 2023 |
-3.69% |
| Jul 2, 2023 |
6.60% |
| Apr 2, 2023 |
-1.01% |
| Jan 1, 2023 |
-18.09% |
| Apr 3, 2022 |
3.94% |
| Oct 3, 2021 |
9.74% |
| Jul 4, 2021 |
-4.38% |
| Apr 4, 2021 |
4.15% |
| Jan 3, 2021 |
10.97% |
| Sep 27, 2020 |
10.19% |
| Jun 28, 2020 |
-15.75% |
| Mar 29, 2020 |
4.85% |
| Dec 29, 2019 |
14.31% |
| Mar 31, 2019 |
17.41% |
| Sep 30, 2018 |
0.71% |
| Jul 1, 2018 |
3.57% |
| Apr 1, 2018 |
7.88% |
| Dec 31, 2017 |
9.86% |
| Oct 1, 2017 |
10.42% |
| Jul 2, 2017 |
1.44% |
| Apr 2, 2017 |
-9.45% |
| Jan 1, 2017 |
1.15% |
| Apr 3, 2016 |
-1.31% |
| Sep 27, 2015 |
7.23% |
| Jun 28, 2015 |
8.83% |
| Mar 29, 2015 |
0.91% |
| Dec 28, 2014 |
38.39% |
| Mar 30, 2014 |
19.20% |
| Sep 29, 2013 |
5.71% |
| Jun 30, 2013 |
9.60% |
| Mar 31, 2013 |
-14.86% |
| Dec 30, 2012 |
-13.89% |
| Sep 30, 2012 |
-0.75% |
| Jul 1, 2012 |
8.07% |
| Apr 1, 2012 |
-0.38% |
